OR WAIT null SECS
October 17, 2025
Article
This systematic review and network meta-analysis was conducted to establish a hierarchy among approved oral JAK inhibitors for severe alopecia areata in adults.
October 16, 2025
These post hoc findings suggest psychosocial burden may improve following hair regrowth with ritlecitinib.
October 13, 2025
This analysis highlights patients with alopecia areata who did not respond to 1 or more JAK inhibitors but saw regrowth after switching to a different JAKi.
October 06, 2025
This review explores the safety of oral JAK inhibitors in inflammatory skin conditions, with 43 real-world studies being highlighted.
September 21, 2025
A compilation of 14 trials presented as late-breaking data at EADV 2025 Congress.
September 20, 2025
Video
New data reveals ritlecitinib's long-term efficacy for alopecia areata, showing sustained hair regrowth in 30% of patients after 3 years.
Adolescents with alopecia areata show promising treatment responses, highlighting the need for diverse therapeutic options to improve outcomes.
September 19, 2025
This EADV interview featured a discussion with Brittany Craiglow, MD, on the topic of developments in the field of alopecia areata treatment.
New data reveals ritlecitinib's long-term effectiveness for alopecia areata, showing significant hair regrowth and sustained benefits in patients.
September 18, 2025
In this interview at EADV, Pasumarthi highlights her team’s late-breaking data on ritlecitinib’s use among patients with cicatricial alopecias.
